|
JP6392770B2
(ja)
|
2012-12-03 |
2018-09-19 |
ノビミューン エスアー |
抗ｃｄ４７抗体およびその使用方法
|
|
CN112877291A
(zh)
|
2014-04-10 |
2021-06-01 |
西雅图儿童医院 (Dba西雅图儿童研究所) |
基因修饰的t细胞产品、其制备方法和用途
|
|
ES2995052T3
(en)
|
2014-04-23 |
2025-02-05 |
Juno Therapeutics Inc |
Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
|
|
KR20210014210A
(ko)
|
2014-05-15 |
2021-02-08 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
|
EP3209690B1
(en)
|
2014-10-20 |
2021-05-05 |
Juno Therapeutics, Inc. |
Methods and compositions for dosing in adoptive cell therapy
|
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
|
HK1256087A1
(zh)
|
2015-08-07 |
2019-09-13 |
Seattle Children's Hospital, Dba Seattle Children's Research Institute |
用於实体瘤靶向的双特异性cart细胞
|
|
CA3006247A1
(en)
|
2015-11-25 |
2017-06-01 |
Legochem Biosciences, Inc. |
Conjugates comprising peptide groups and methods related thereto
|
|
EP3380126A4
(en)
|
2015-11-25 |
2019-07-24 |
LegoChem Biosciences, Inc. |
ANTIBODY-ACTIVE CONJUGATES WITH BRANCHED LINKERS AND ASSOCIATED METHODS
|
|
CA3006242A1
(en)
|
2015-11-25 |
2017-06-01 |
Legochem Biosciences, Inc. |
Conjugates comprising self-immolative groups and methods related thereto
|
|
SG10202012157QA
(en)
|
2016-06-07 |
2021-01-28 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Chimeric antigen receptor and car-t cells that bind bcma
|
|
CN111848801B
(zh)
*
|
2016-09-06 |
2022-10-11 |
上海吉倍生物技术有限公司 |
一种抗cd19抗体及其制备方法和用途
|
|
AU2017353936A1
(en)
*
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
|
CN108610420B
(zh)
*
|
2016-12-13 |
2023-09-26 |
科济生物医药（上海）有限公司 |
抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
|
|
EP4032550A3
(en)
|
2017-01-05 |
2022-10-19 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
|
CA3049652A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
CA3053305A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Mapp Biopharmaceutical, Inc. |
Monoclonal antibodies and cocktails for treatment of ebola infections
|
|
ES2988795T3
(es)
|
2017-02-27 |
2024-11-21 |
Juno Therapeutics Inc |
Composiciones, artículos de fabricación y métodos relacionados con la dosificación en terapia celular
|
|
JP7359751B2
(ja)
|
2017-03-14 |
2023-10-11 |
ジュノー セラピューティクス インコーポレイテッド |
極低温保管のための方法
|
|
AU2018245749A1
(en)
|
2017-03-27 |
2019-10-03 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
CA3056439A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
AU2018246806B2
(en)
|
2017-03-29 |
2022-05-12 |
Ligachem Biosciences Inc. |
Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
|
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
|
JOP20180042A1
(ar)
*
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
KR20200054160A
(ko)
|
2017-06-02 |
2020-05-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
|
|
CN110997920A
(zh)
|
2017-06-07 |
2020-04-10 |
英特拉克森公司 |
新型细胞标签的表达
|
|
EP3441471A1
(en)
*
|
2017-08-08 |
2019-02-13 |
CEVEC Pharmaceuticals GmbH |
Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
|
|
KR20250096881A
(ko)
|
2017-08-09 |
2025-06-27 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포를 제조하기 위한 방법 및 조성물
|
|
WO2019032927A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
|
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
|
US20200292526A1
(en)
|
2017-09-07 |
2020-09-17 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
|
WO2019055399A1
(en)
*
|
2017-09-12 |
2019-03-21 |
Igc Bio, Inc. |
ANTI-VEGF ANTIBODIES
|
|
US10501539B2
(en)
*
|
2017-09-15 |
2019-12-10 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with anti-CD19 immunotherapy
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
KR20250029294A
(ko)
|
2017-09-22 |
2025-03-04 |
우시 바이올로직스 아일랜드 리미티드 |
신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
|
|
US20190092818A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
|
EA202090812A1
(ru)
|
2017-09-22 |
2020-08-07 |
Уси Байолоджикс Аэлэнд Лимитед |
Новые биспецифические полипептидные комплексы
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
SG11202003657VA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Process for producing a t cell composition
|
|
WO2019089855A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
EP3704156A1
(en)
|
2017-11-03 |
2020-09-09 |
Sorrento Therapeutics, Inc. |
Cd38-directed chimeric antigen receptor constructs
|
|
AU2018365080B2
(en)
|
2017-11-10 |
2025-07-24 |
Jura Bio, Inc. |
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
|
|
CN111989106A
(zh)
|
2017-12-01 |
2020-11-24 |
朱诺治疗学股份有限公司 |
基因工程化细胞的给药和调节方法
|
|
CN111465616B
(zh)
*
|
2017-12-06 |
2023-08-01 |
艾克隆株式会社 |
特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途
|
|
AU2018379091A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
|
WO2019113557A1
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
|
SG11202005217VA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Phenotypic markers for cell therapy and related methods
|
|
CN111511754B
(zh)
|
2017-12-20 |
2023-09-12 |
捷克共和国有机化学与生物化学研究所 |
活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
|
|
EP3728283B1
(en)
|
2017-12-20 |
2023-11-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
EP3730519B1
(en)
*
|
2017-12-22 |
2023-09-13 |
AbClon Inc. |
Antibody or antigen-binding fragment thereof that specifically recognizes b cell malignancies, chimeric antigen receptor comprising same, and uses thereof
|
|
CN107903326B
(zh)
*
|
2018-01-02 |
2020-06-30 |
广东省人民医院(广东省医学科学院) |
包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
|
|
CN108047332B
(zh)
*
|
2018-01-15 |
2021-08-24 |
阿思科力(苏州)生物科技有限公司 |
以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
KR20200128014A
(ko)
|
2018-01-31 |
2020-11-11 |
셀진 코포레이션 |
입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
|
|
SG11202007156QA
(en)
|
2018-02-09 |
2020-08-28 |
Nat Univ Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
WO2019160882A1
(en)
|
2018-02-13 |
2019-08-22 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US12258378B2
(en)
*
|
2018-03-14 |
2025-03-25 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, T cell immune modulating antibodies and methods for using the same
|
|
EA202091982A1
(ru)
*
|
2018-03-14 |
2021-06-10 |
Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) |
Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
WO2019200056A2
(en)
|
2018-04-12 |
2019-10-17 |
Vivo-Til Therapeutics Inc. |
Viral vectors and packaging cell lines
|
|
AR114789A1
(es)
*
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
EP3787751A1
(en)
|
2018-05-03 |
2021-03-10 |
Juno Therapeutics, Inc. |
Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
CA3099680A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Legochem Biosciences, Inc. |
Compositions and methods related to anti-cd19 antibody drug conjugates
|
|
US10703733B2
(en)
|
2018-05-14 |
2020-07-07 |
Gilead Sciences, Inc. |
MCL-1 inhibitors
|
|
BR112020026746A2
(pt)
|
2018-07-13 |
2021-03-30 |
Gilead Sciences, Inc. |
Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
|
|
US12486514B2
(en)
|
2018-08-29 |
2025-12-02 |
National University Of Singapore |
Method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
|
CN112955435B
(zh)
|
2018-10-24 |
2024-09-06 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
|
FI3873903T3
(fi)
|
2018-10-31 |
2024-03-26 |
Gilead Sciences Inc |
Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
|
|
US12522660B2
(en)
|
2018-10-31 |
2026-01-13 |
C3S2 Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
KR102658602B1
(ko)
|
2018-10-31 |
2024-04-19 |
길리애드 사이언시즈, 인코포레이티드 |
Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
|
|
CA3117720A1
(en)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
|
US12146157B2
(en)
*
|
2018-11-07 |
2024-11-19 |
Crispr Therapeutics Ag |
Anti-PTK7 immune cell cancer therapy
|
|
SG11202105084VA
(en)
|
2018-11-16 |
2021-06-29 |
Juno Therapeutics Inc |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
|
ES2986007T3
(es)
|
2018-11-30 |
2024-11-08 |
Juno Therapeutics Inc |
Métodos para la dosificación y el tratamiento de neoplasias malignas de linfocitos B en terapia celular adoptiva
|
|
FI3886875T3
(fi)
|
2018-11-30 |
2024-07-23 |
Juno Therapeutics Inc |
Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
|
|
WO2020114358A1
(zh)
*
|
2018-12-03 |
2020-06-11 |
广东东阳光药业有限公司 |
Cd19抗体及其应用
|
|
CN120005921A
(zh)
|
2018-12-12 |
2025-05-16 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
CN109734813B
(zh)
*
|
2019-01-28 |
2022-06-17 |
广东昭泰体内生物医药科技有限公司 |
一种嵌合抗原受体及其应用
|
|
JP6821230B2
(ja)
*
|
2019-02-04 |
2021-01-27 |
国立大学法人愛媛大学 |
ＣＡＲライブラリおよびｓｃＦｖの製造方法
|
|
JP7593646B2
(ja)
|
2019-02-20 |
2024-12-03 |
シティ・オブ・ホープ |
Ｂａｆｆ－ｒ／ｃｄ１９を標的としたキメラ抗原受容体修飾ｔ細胞とその使用
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
EP3935065A1
(en)
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
EP3934757B1
(en)
|
2019-03-07 |
2023-02-22 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CA3129011C
(en)
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
US20230065784A1
(en)
|
2019-03-21 |
2023-03-02 |
City Of Hope |
Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
AU2020265749A1
(en)
|
2019-05-01 |
2022-01-06 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified CD247 locus, related polynucleotides and methods
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
MA56206A
(fr)
|
2019-06-12 |
2022-04-20 |
Juno Therapeutics Inc |
Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie
|
|
CN114286863A
(zh)
*
|
2019-06-21 |
2022-04-05 |
甘李药业股份有限公司 |
一种双特异性嵌合抗原受体
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
CN112210007B
(zh)
*
|
2019-07-11 |
2022-07-12 |
华夏英泰（北京）生物技术有限公司 |
一种cd19抗原高亲和力的抗体以及包含其cd19单链抗体区的嵌合抗原受体
|
|
AU2020317009A1
(en)
*
|
2019-07-19 |
2022-02-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric antigen receptors containing Glypican 2 binding domains
|
|
EP3769816A1
(en)
*
|
2019-07-25 |
2021-01-27 |
Ospedale Pediatrico Bambino Gesù |
Car-cd123 vector and uses thereof
|
|
US20220298222A1
(en)
|
2019-08-22 |
2022-09-22 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
|
IL292319B2
(en)
|
2019-10-30 |
2026-01-01 |
C3S2 Gmbh |
Cell selection and/or stimulation devices and methods of use
|
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
AU2020375149A1
(en)
*
|
2019-10-31 |
2022-05-12 |
Incyte Corporation |
Sequential anti-CD19 therapy
|
|
US20220401483A1
(en)
|
2019-11-07 |
2022-12-22 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
CN115398231A
(zh)
|
2019-12-06 |
2022-11-25 |
朱诺治疗学股份有限公司 |
与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
CN115397974A
(zh)
|
2020-01-23 |
2022-11-25 |
儿童医疗中心有限公司 |
由人类多能干细胞进行无基质t细胞分化
|
|
US20230071910A1
(en)
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
IL295384A
(en)
|
2020-02-12 |
2022-10-01 |
Juno Therapeutics Inc |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
IL296242A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Methods for producing engineered memory-like nk cells and preparations containing them
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CR20220547A
(es)
|
2020-05-01 |
2022-12-15 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina inhibidores de cd73
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
EP4150640A1
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
|
JP2023526278A
(ja)
|
2020-05-13 |
2023-06-21 |
ジュノー セラピューティクス インコーポレイテッド |
組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
KR102594083B1
(ko)
|
2020-07-07 |
2023-10-25 |
칸큐어 엘엘씨 |
Mic 항체 및 결합제 및 이의 사용 방법
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
CN116848147A
(zh)
|
2020-11-20 |
2023-10-03 |
先声再明医药有限公司 |
Cd19人源化抗体及其应用
|
|
IL302744A
(en)
|
2020-11-24 |
2023-07-01 |
Lyell Immunopharma Inc |
Methods for production, total preparations and methods of using regenerated T cells
|
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
AU2021413365A1
(en)
|
2020-12-30 |
2023-07-20 |
Precigen, Inc. |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
|
TW202242121A
(zh)
|
2021-01-11 |
2022-11-01 |
美商薩那生物科技公司 |
靶向cd8之病毒載體之用途
|
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
|
JP2024513054A
(ja)
|
2021-03-29 |
2024-03-21 |
ジュノー セラピューティクス インコーポレイテッド |
リンパ腫の治療のためのｃａｒ ｔ細胞療法および免疫調節化合物の組合せ
|
|
US20240181052A1
(en)
|
2021-03-29 |
2024-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
KR20240018454A
(ko)
|
2021-05-06 |
2024-02-13 |
주노 테라퓨틱스 게엠베하 |
T 세포의 자극 및 형질도입 방법
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
WO2023280297A1
(zh)
|
2021-07-09 |
2023-01-12 |
江苏先声药业有限公司 |
Cd19抗体及其应用
|
|
KR20240034234A
(ko)
|
2021-07-14 |
2024-03-13 |
2세븐티 바이오, 인코포레이티드 |
항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
|
|
TW202321457A
(zh)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
靶向ｃｄ４之病毒載體之用途
|
|
EP4381050A4
(en)
*
|
2021-08-06 |
2025-10-08 |
Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute |
T CELL MANUFACTURING PROCESSES
|
|
KR20240099280A
(ko)
*
|
2021-10-18 |
2024-06-28 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체에 대한 신호전달 도메인
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4448549A2
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CN119013393A
(zh)
|
2022-01-28 |
2024-11-22 |
朱诺治疗学股份有限公司 |
制造细胞组合物的方法
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
CA3246975A1
(en)
*
|
2022-03-28 |
2023-10-05 |
Vygen-Bio, Inc. |
Genetically modified antibody-resistant cells for adoptive cell therapy
|
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
CN119546327A
(zh)
|
2022-04-08 |
2025-02-28 |
再生元制药公司 |
多部分受体和信号传导复合物
|
|
CN114716558B
(zh)
*
|
2022-04-12 |
2023-05-05 |
骏蓦(北京)生物科技有限公司 |
一种双特异性抗体及其治疗癌症的应用
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4525899A1
(en)
|
2022-05-17 |
2025-03-26 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
US20250381272A1
(en)
|
2022-06-22 |
2025-12-18 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
|
EP4547230A1
(en)
|
2022-06-29 |
2025-05-07 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
EP4583876A1
(en)
|
2022-09-08 |
2025-07-16 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
IL320319A
(en)
|
2022-11-04 |
2025-06-01 |
Umoja Biopharma Inc |
Lentivirus particles displaying fusion molecules and their uses
|
|
TW202434735A
(zh)
|
2022-11-04 |
2024-09-01 |
美商烏莫賈生物製藥股份有限公司 |
展示黏著分子融合的顆粒
|
|
EP4615960A1
(en)
|
2022-11-09 |
2025-09-17 |
C3S2 GmbH |
Methods for manufacturing engineered immune cells
|
|
CN120712102A
(zh)
|
2022-12-13 |
2025-09-26 |
朱诺治疗学股份有限公司 |
对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN121002052A
(zh)
|
2023-02-03 |
2025-11-21 |
C3S2 有限公司 |
用于非病毒生产工程化免疫细胞的方法
|
|
CN121127253A
(zh)
|
2023-02-28 |
2025-12-12 |
朱诺治疗学股份有限公司 |
治疗系统性自身免疫性疾病的细胞疗法
|
|
AU2024244733B2
(en)
|
2023-03-31 |
2025-12-11 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
EP4698665A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
CN121311765A
(zh)
|
2023-04-18 |
2026-01-09 |
朱诺治疗学股份有限公司 |
评估治疗性细胞组合物的效力的细胞毒性测定
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
WO2024226858A1
(en)
|
2023-04-26 |
2024-10-31 |
Juno Therapeutics, Inc. |
Methods for viral vector manufacturing
|
|
KR20260026101A
(ko)
|
2023-05-23 |
2026-02-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025171383A2
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens and related methods and uses
|
|
WO2025171388A1
(en)
|
2024-02-09 |
2025-08-14 |
Dispatch Biotherapeutics, Inc. |
Engineered cancer antigens with modified domains and related methods and uses
|
|
WO2025231174A1
(en)
|
2024-04-30 |
2025-11-06 |
Umoja Biopharma, Inc. |
Manufacturing viral particles
|
|
WO2025235604A1
(en)
|
2024-05-08 |
2025-11-13 |
Umoja Biopharma, Inc. |
Fusion protein for use as immune cell engager
|
|
WO2025235851A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026020171A2
(en)
|
2024-07-19 |
2026-01-22 |
Aera Therapeutics, Inc. |
Chimeric antigen receptor constructs
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
US20260061053A1
(en)
|
2024-08-28 |
2026-03-05 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases
|